Abstract:Objective To investigate the effects of MK-801, a selective non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, on sensorimotor gating of mice and determine the appropriate dose for the deficient sensorimotor gating of schizophrenia model in mice. Methods Different doses of MK-801 (0.125, 0.25, 0.50 mg/kg) were used to establish the schizophrenia model of deficient sensorimotor gating in mice. Prepulse inhibition (PPI), startle amplitude and habituation in mice were measured using six SR-LAB startle chambers to determine the pharmacological actions of different doses of MK-801. Results ①At the 12dB prepulse level, the PPI in MK-801 at 0.125, 0.25 or 0.50 mg/kg were (28.7%±4.8%), (27.5%±5.6%) or (9.2%±4.0%), respectively. Compared with the control group (53%±4.5%), MK-801 significantly disrupted PPI in a dose-dependent manner (P<0.01).②MK-801 at the dose of 0.50 mg/kg significantly increased the startle amplitude by 53% than the control group (P<0.001). ③ The habituation of MK-801 at 0.50 mg/kg was (-2.6%±10%). Compared with the control group, MK-801 (0.50 mg/kg) impaired habituation of the acoustic startle response (P<0.001). Conclusions MK-801 induces disruption of sensorimotor gating in mice and increases the startle response. MK-801 at 0.50 mg/kg can be used as the appropriate dose for the deficient sensorimotor gating of schizophrenia model in mice.

Establishment of a schizophrenia mouse model of deficient sensorimotor gating by MK-801